News
15h
Zacks Investment Research on MSNRegeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...
Walt Disney ( DIS) will release its results on Wednesday, with attention on its media networks, theme parks, and streaming services. Analysts expect earnings of $1.47 per share and $23.7bn in revenue, ...
Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Tempus AI TEM and NVIDIA NVDA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing ...
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
14d
Zacks Investment Research on MSNCan Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T2D) and Wegovy for obesity. Ozempic and Wegovy include the same ...
Takeaways The Novo Nordisk Foundation and Denmark's Export and Investment Fund will each invest €40 million in a Microsoft-powered quantum computer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results